New Checkpoint Inhibitors Activating Both T and NK Cells
Cancer treatment has changed dramatically in the last decade -- immunotherapy has revolutionized cancer treatment.
As the star of immunotherapy, immune checkpoint inhibitors (ICIs) this year won the Nobel Prize in physiology or medicine---In the case of single drug use, it has broken the conventional cancer treatment efficacy and greatly improved the 5-year survival rate of cancer patients, including many previously helpless cancer types -- metastatic melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, Hodgkin's lymphoma and so on. The disadvantage is that the efficiency of single drug use is still not satisfactory to us, only 20%~30%. Medicine is greedy, we want to cure every patient.
Therefore, new immunocheckpoint inhibitors have been continuously explored. In the latest development, a new immune checkpoint has been identified -- NKG2A. Not only does it activate our T cells, but it also activates NK cells, which are our first line of defense against cancer. The research was published in the latest issue of the top journal Cell.
Regarding T cells, our Dldevelop has relevant Elisa kits such as Human Linker For Activation Of T-Cell (LAT) ELISA Kit and Mouse Linker For Activation Of T-Cell (LAT) ELISA Kit. You can contact us directly or visit our website for more information
As the star of immunotherapy, immune checkpoint inhibitors (ICIs) this year won the Nobel Prize in physiology or medicine---In the case of single drug use, it has broken the conventional cancer treatment efficacy and greatly improved the 5-year survival rate of cancer patients, including many previously helpless cancer types -- metastatic melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, Hodgkin's lymphoma and so on. The disadvantage is that the efficiency of single drug use is still not satisfactory to us, only 20%~30%. Medicine is greedy, we want to cure every patient.
Therefore, new immunocheckpoint inhibitors have been continuously explored. In the latest development, a new immune checkpoint has been identified -- NKG2A. Not only does it activate our T cells, but it also activates NK cells, which are our first line of defense against cancer. The research was published in the latest issue of the top journal Cell.
Regarding T cells, our Dldevelop has relevant Elisa kits such as Human Linker For Activation Of T-Cell (LAT) ELISA Kit and Mouse Linker For Activation Of T-Cell (LAT) ELISA Kit. You can contact us directly or visit our website for more information
